9-ING-41 in Patients With Advanced Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer|Pancreatic Cancer|Sarcoma|Renal Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms|Acute T Cell Leukemia Lymphoma
Interventions: DRUG: 9-ING-41|DRUG: Gemcitabine - 21 day cycle|DRUG: Doxorubicin.|DRUG: Lomustine|DRUG: Carboplatin.|DRUG: Nab paclitaxel.|DRUG: Paclitaxel.|DRUG: Gemcitabine - 28 day cycle|DRUG: Irinotecan
Sponsor: Actuate Therapeutics Inc.